Find similar content

Source channel @githubtrending · Post #14873 · Jun 28

#rust#2d_graphics#art#compositor#design#graphic_design#graphics_editor#image_generation#image_manipulation#image_processing#node_editor#node_graph#photo_editing#photo_editor#procedural#procedural_art#procedural_drawing#svg_editor#vector_editor Graphite is a free, open-source 2D graphics editor that combines vector and raster tools with a unique hybrid workflow using layers and nodes. It lets you create detailed vector art and designs with nondestructive editing, meaning you can change your work anytime without losing quality. The node-based system offers powerful, flexible control like visual programming, while the layer system keeps things simple and familiar. This makes it easy to create complex graphics, animations, and effects all in one tool. Graphite is still evolving but aims to be a versatile, all-in-one creative platform accessible to everyone, helping you unleash your artistic potential efficiently[1][2][4]. https://github.com/GraphiteEditor/Graphite

Hashtags

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选

Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

Find similar View

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Hashtags

#hongkong #pharmaceuticals #biotech #innovation #stockmarket #healthcare #drugdevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

Find similar View

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment

Hashtags

#biotech #funding #cancer #immunedisorders #california #clinicalstage #therapies #investment #healthcare #innovation #pepromenebio #pharmaceuticals #medicalresearch #drugdevelopment